Psychoactive Substances: Transforming the Paradigm for Treating Mental Health Disorders in the Post-Pandemic Era
- 23 December 2024
- journal article
- research article
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 41 (3) , 536-538
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illnessMolecular Psychiatry, 2023
- Is Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All DrugsJournal of Medicinal Chemistry, 2023
- Psilocybin for the treatment of anorexia nervosaNature Medicine, 2023
- Psychedelics reopen the social reward learning critical periodNature, 2023
- Psychedelics promote plasticity by directly binding to BDNF receptor TrkBNature Neuroscience, 2023
- SnapShot: Psychedelics and serotonin receptor signalingCell, 2023
- Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signalingProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2022
- Author Correction: Structural basis of ketamine action on human NMDA receptorsNature, 2021
- Trial of Psilocybin versus Escitalopram for DepressionNew England Journal of Medicine, 2021
- Psychedelics Promote Structural and Functional Neural PlasticityCell Reports, 2018